Anticancer Drug Development Guide

1. Front Matter

   Pages i-xiv

   PDF

2. In Vitro Methods

   1. Front Matter

      Pages 1-1

      PDF

   2. High-Volume Screening

      • Michel Pagé

      Pages 3-21

   3. High-Throughput Screening in Industry

      • Michael D. Boisclair, David A. Egan, Kety Huberman, Ralph Infantino

      Pages 23-39

   4. The NCI Human Tumor Cell Line (60-Cell) Screen

      • Michael R. Boyd

      Pages 41-61

   5. Human Tumor Screening

      • Axel-R. Hanauske, Susan G. Hilsenbeck, Daniel D. Von Hoff

      Pages 63-76

3. In Vivo Methods

   1. Front Matter

      Pages 77-77

      PDF

   2. Murine L1210 and P388 Leukemias

      • William R. Waud

      Pages 79-97

   3. In Vivo Methods for Screening and Preclinical Testing

      • Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh et al.

      Pages 99-123

   4. Human Tumor Xenograft Models in NCI Drug Development

      • Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes, William R. Waud

      Pages 125-152

   5. NCI Specialized Procedures in Preclinical Drug Evaluations

      • Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, Sherman F. Stinson

      Pages 153-182

   6. Patient-Like Orthotopic Metastatic Models of Human Cancer

      • Robert M. Hoffman

      Pages 183-212

   7. Preclinical Models for Combination Therapy

      • Beverly A. Teicher

      Pages 213-242

   8. Models for Biomarkers and Minimal Residual Tumor

      • Beverly A. Teicher

      Pages 243-258

   9. Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development

      • David M. Vail, Douglas H. Thamm

      Pages 259-284

4. Nonclinical Testing to Support Human Trials

   1. Front Matter

      Pages 285-285

      PDF

   2. Nonclinical Testing

      • Denis Roy, Paul A. Andrews

      Pages 287-311

   3. Nonclinical Testing for Oncology Drug Products

      • Paul A. Andrews, Denis Roy

      Pages 313-323

   4. Nonclinical Testing for Oncology Biologic Products

      • Carolyn M. Laurençot, Denis Roy, Paul A. Andrews

      Pages 325-335

5. Clinical Testing

   1. Front Matter

      Pages 337-337

      PDF

This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.

• cancer
• cell
• clinical trial
• drug
• drug development
• drug discovery
• leukemia
• research
• screening
• tumor

From Reviews of the First Edition:

"...traces the critically important pathway by which a 'molecule' becomes an 'an anticancer agent'."
-Unlisted Drugs

"...this book is a must for all oncology fellows and junior faculty interested in drug development and will be a welcome addition on the bookshelf of all oncologists, pharmacists and other professionals interested in understanding this complex area." -Journal of Clinical Oncology

• Oncology Discovery and Research, Genzyme Corporation, Framingham, USA

  Beverly A. Teicher

• Preclinical Sciences, Aton Pharma Inc., Tarrytown, USA

  Paul A. Andrews

Policies and ethics